1 Hart C A, Beeching N J, Duerden B I. Tuberculosis into the next century[J].J med Microbiol, 1996,44: 1 - 34.
2 Reich man L B. multidrug resistancein the world: the present situation[j]. J Chemotherapy, 1996,42(Suppl 2) :2.
3 Croflon J, Chanlet P, Maher D, et al. Quinolones for the management of drug-resistant tuberculosisf M], WHO/TB 196,210,1997:26.
4 Alangaden G J, Lerner S A. The clinical use of fluoroquinolones for the treatment of Mycobacterial diseases [J]. Clia Infect Dis, 1997,25:1213~1221.
5 Maranetra K N. Quinolones and multidrug-resistant tuberculosis[J] .Chemotherapy, 1999,45: 12~18.
6 Wang J C. DNA topoisomerases[ J]. Annu. Rev. Biochem, 1985,54:665~697.
7 Mouneimne H, Robert J, Jarlier V, et al. Type II Topoisomerase mutations in ciprofloxacin resistant strains of pseudomonas aeruginosa[j]. Agents and Chemotherapy, 1999,43(1) :62 ~66.
8 Cambau E, Cutmann L. Mechanism of resistance to quintolos[J].Drugs, 1993;45(8upple3):15-23.
9 Piddlck L J V. Mechanisms of resistance to fluoroquinolones : state-of-the-art 1992 - 1994[j]. Drugs, 1995,49:29~35.
10 Kumagai Y, Kato J I, Hoahino K,et al. Quinolone - resistant mutants of Escherichia coli DNA topoisomerase IV parC gene[j]. Antimicrobial Agents and Chemotherapy 1996,40(3) :710~714.
11 Schmitz F J, Jones M E, Hofmann B, et al. Charatcerization of grlA, grlB, gyrA and gyrB mutations in 116 unrelated isolates of Staphylococcus aureus and effets of mutations on ciprofloxacin MIC [J]. Antimicrobial Agents and Chemotherapy 1998; 42(5): 1249~1252.
12 Munoz Bellido J L, Manzanares M A A, Andres J M A,et al. Efflux pump mediated quinolone resistante in Staphylococcus aureus strainswild type for gyrA gyrB grlA and norA [J]. Antimicrobial Agents and Chemotherapy, 1998,42(8): 1917 - 1922.
13 Takiff H E,Salazar L,Guerrern C, Huang B, Kreisworth ST,et al.Cloning and nucleotide sequece of Mycobacterium tuberculosis gyrA and gyrB genes and detection of quinolone resistance mutations[J].Antimicro Agents Chemother, 1994,38:773 ~780.
14 Alangaden G J, Manavathu EK, etal. Characterization of fluoroquinolone -resistant mutant strains of mycobacterium tuberculosis selected in the laboratory and isolated from patients[J]. Atimicrobial agents and chemotherapy . 1995;39(8): 1700~1703.
15 Guillemin I,Cambau E and Jarlier V. Sequences of conserved region in the A subunit of DNA Gyrase from Nine Species of the Genus Mycobacterium: Phylogenetic analysis and implication for intrinsic susceptibility to quinolones[J]. Atimicrobial agents and chemotherapy, 1995;39(9);2145~2149.
16 Kocagoz T, Hackbarth C J, unsal z et al. Gyrase mutations in laboralory selected, fluoroquinolone - resistance, mutants of Mycobacterium tuberculosis H37Ra [ J ]. Antimicrob Agents Chemother.1996,40(8):1768-1774.
17 Guillemin 11 Jarlier V and Cambau E. Correlation between quinolone susceptibility patterns and sequences in the A and B subunits of DNA Gyrase in Mycobacteria[j]. Antimicrobial agents and chemo-therapy.,1998;42(8):2084 ~2088.
18 Lee A S, Tang L L, Lim I H, Wong S Y, Characterization of pyrazinaraide and ofloxacin resistance among drug resistant Mycobacterium tuberculosis isolates from Singapore[J]. Int J Infect Dis 2002 Mar;6(l):48-51.
19 Onodera Y, Tanaka M, Sato K. Inhibitory activity of quinolones against DNA gyrase of Mycobacterium tuberculosis[J]. Journal of Antimicrobial Chemotherapy,2001,47:447 ~450.
20 Schmitz F J, Jones M E, Hofmann B, et al. Charatcerization of grlA, grlB, gyrA and gyrB mutations in 116 unrelated isolates of Staphylococcus aureus and effets of mutations on ciprofloxacin MIC [J]. Antimicrobial Agents and Chemotherapy 1998; 42(5):1249-1252.
21 Kumagai Y, Kato JI,Hoshino K, et al. Quinolone - resistant mutants of Escherichia coli DNA topoisomerase IV parC gene[J]. Antimicrobial Agents and Chemotherapy, 1996;40(3) :1
22 Cole ST,Brosch R,et al . Deciphering the biology of Mycobacteri-um tuberculosis from the complete genome sequence [J]. Nature 393:537-544.
|